Supplements · Metabolic & Cardiometabolic

coenzyme Q10 decreases blood pressure

In plain terms: Does CoQ10 lower blood pressure?

Contested Supplements 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 0.15

Contested—older small trials say yes but a Cochrane review and newer trials found no reliable effect, so it's not a dependable blood-pressure treatment.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

6 support 3 contradict 0 tested null 3 mixed · 12 sources, 9 independent groups

What the evidence shows

Genuinely contested. Older/smaller trials and a GRADE dose-response MA (26 RCTs, n=1831; SBP −4.77 mmHg in cardiometabolic disease, U-shaped optimum ~100–200 mg/day) point to a modest reduction — but the disconfirming evidence is substantial: a Cochrane review judged the trials unreliable/insufficient, a controlled-hypertension RCT with 24-h ambulatory BP found no effect, and healthy…

Cochrane has no ruling yet see how our grade compares ▾

Cochrane review 2016 · moderate (GRADE) Not directly comparable

“This review provides moderate-quality evidence that coenzyme Q10 does not have a clinically significant effect on blood pressure.”

Not directly comparable: their review asks a different question or reports an outcome we do not grade, so it neither corroborates nor contradicts this claim.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (12)

Source	Grade	Stance	Quality	Finding
Hosseini Roknabadi SM et al 2025 · study_type: observational	observational	supports	low	Narrative review of mechanistic pathways (antioxidant, anti-inflammatory, eNOS, arterial stiffness) by which CoQ10 may lower BP; states clinical trials 'suggest' CoQ10 may lower SBP/DBP in essential hypertension, mostly as adjunctive therap
Zhao et al. 2022 · Adv Nutr	meta-analysis	supports	moderate	GRADE dose-response MA (26 RCTs, n=1831): SBP -4.77 mmHg in cardiometabolic disease; U-shaped, 100-200 mg/d optimal; GRADE moderate (SBP), lower for DBP.
Burke et al. 2001 · South Med J	RCT	supports	moderate	Double-blind RCT (isolated systolic hypertension, n=83): oral CoQ10 lowered systolic BP vs placebo.
Mori et al. 2009	RCT	mixed	low	RCT in CKD: CoQ10 had only modest BP/heart-rate effects (omega-3 drove the clearer BP reduction).
Karimi et al. 2025 · Int J Cardiol Cardiovasc Risk Prev	meta-analysis	mixed	moderate	SR/MA of CoQ10 on BP and heart rate in adults: prior results inconsistent; effect on BP/HR not consistently significant across populations.
Li et al. 2025 · Clin Ther	meta-analysis	mixed	moderate	SR/MA in T2D: CoQ10 effects on lipid profile and BP suggested but not uniformly significant.
Rosenfeldt et al. 2003 · Biofactors	meta-analysis	supports	low	SR of 8 hypertension trials: mean SBP -16 / DBP -10 mmHg with CoQ10 (older, small trials). QUALITY DOWNGRADED moderate->low 2026-07-22: pre-GRADE synthesis of small trials whose pooled effect is ~3x the -4.77 mmHg found by the 2022 GRADE dose-response MA (26 RCTs, n=1831), and Cochrane independently judged this trial base unreliable/insufficient. Classic small-study/publication-bias signature.
Porta DJ et al 2026 · study_type: animal	animal	supports	moderate	Uninephrectomized Wistar rats on high-sodium diet; CoQ10 200 mg/kg/day prevented BP rise vs. high-sodium-only group (128±2.8 vs 119.2±3.7 mmHg, P<0.05), via preserved pressure-natriuresis and reduced oxidative stress.
Young et al. 2012 · Am J Hypertens	RCT	contradicts	moderate	Crossover RCT (metabolic syndrome, 24-h ambulatory BP): CoQ10 did NOT significantly reduce blood pressure.
Shah et al. 2007 · Ann Pharmacother	RCT	contradicts	low	RCT in healthy individuals: no significant hemodynamic/BP effect of CoQ10 (and no QTc prolongation).
Ho et al. 2016 · Cochrane Database Syst Rev	meta-analysis	contradicts	moderate	Cochrane review (primary hypertension): trials unreliable/insufficient — uncertain that CoQ10 lowers BP; no clinically significant effect established.
Singh et al. 1999 · J Hum Hypertens	RCT	supports	moderate	Double-blind RCT (hypertension + CAD): CoQ10 60 mg bid lowered SBP/DBP and improved insulin/glucose vs B-vitamin control.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.